Nasdaq Ruby News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rubius Therapeutics (NASDAQ:RUBY – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings. Institutional & Insider Ownership 55.4% of Agenus shares […]

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

Rubius Therapeutics (NASDAQ:RUBY – Get Rating) issued its earnings results on Tuesday. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01), MarketWatch Earnings reports. During the same period in the previous year, the firm posted ($0.51) earnings per share. Shares of NASDAQ RUBY traded up $0.04 during midday […]

Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) Director David R. Epstein purchased 30,000 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $1.44 per share, with a total value of $43,200.00. Following the acquisition, the director now directly owns 4,720,012 shares of […]